Head-To-Head Survey: Absci (ABSI) and The Competition

Absci (NASDAQ:ABSI – Get Rating) is one of 40 public companies in the “Commercial physical research” industry, but how does it compare to its peers? We will compare Absci to related companies based on the strength of its analyst recommendations, profitability, institutional ownership, dividends, earnings, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations and price targets for Absci and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Absci	1	3	3	0	2.29
Absci Competitors	39	576	1184	22	2.65

Absci currently has a consensus target price of $20.40, indicating a potential upside of 471.43%. As a group, “Commercial physical research” companies have a potential upside of 57.63%. Given Absci’s higher probable upside, analysts plainly believe Absci is more favorable than its peers.

Earnings & Valuation

This table compares Absci and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Absci	$4.78 million	-$100.96 million	-1.07
Absci Competitors	$2.80 billion	$97.54 million	12.88

Absci’s peers have higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Absci and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Absci	-2,633.14%	-36.19%	-22.99%
Absci Competitors	-260.35%	-8.17%	-2.92%

Institutional and Insider Ownership

40.0% of Absci shares are owned by institutional investors. Comparatively, 59.5% of shares of all “Commercial physical research” companies are owned by institutional investors. 11.4% of shares of all “Commercial physical research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Absci peers beat Absci on 11 of the 12 factors compared.

About Absci (Get Rating)

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Want More Great Investing Ideas?